PRRT with long-acting hormone therapy for neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with a neuroendocrine tumor
- A soft-tissue tumor larger than 2 cm that can be seen on scans
- Able to stop long-acting somatostatin analogues for 4-6 weeks before treatment
- Good enough daily activity level (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests whether it's safe to stop somatostatin analogues (SSAs) after PRRT (a type of radiation therapy for neuroendocrine tumors). It is for people with midgut, hindgut, or pancreatic NETs that have not responded to SSAs and now need PRRT.
This Phase 2 study compares a more personalized (precision) radiation dose plan to the standard dose plan using Lu-177-DOTATOC for people with neuroendocrine neoplasms (NEN) that have worsened or caused major symptoms despite usual treatments. The goal is to see if better planning can improve treatment delivery while staying safe.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.